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Abstract
With a large number of DNA and protein sequences already known, the crucial question is to find
out how the biological function of these macromolecules is "written" in the sequence of nucleotides
or amino acids. Biological processes in any living organism are based on selective interactions
between particular bio-molecules, mostly proteins. The rules governing the coding of a protein's
biological function, i.e. its ability to selectively interact with other molecules, are still not elucidated.
In addition, with the rapid accumulation of databases of protein primary structures, there is an
urgent need for theoretical approaches that are capable of analysing protein structure-function
relationships. The Resonant Recognition Model (RRM) [1,2] is one attempt to identify the
selectivity of protein interactions within the amino acid sequence. The RRM [1,2] is a physico-
mathematical approach that interprets protein sequence linear information using digital signal
processing methods. In the RRM the protein primary structure is represented as a numerical series
by assigning to each amino acid in the sequence a physical parameter value relevant to the protein's
biological activity. The RRM concept is based on the finding that there is a significant correlation
between spectra of the numerical presentation of amino acids and their biological activity. Once
the characteristic frequency for a particular protein function/interaction is identified, it is possible
then to utilize the RRM approach to predict the amino acids in the protein sequence, which
predominantly contribute to this frequency and thus, to the observed function, as well as to design
de novo peptides having the desired periodicities. As was shown in our previous studies of fibroblast
growth factor (FGF) peptidic antagonists [2,3] and human immunodeficiency virus (HIV) envelope
agonists [2,4], such de novo designed peptides express desired biological function. This study utilises
the RRM computational approach to the analysis of oncogene and proto-oncogene proteins. The
results obtained have shown that the RRM is capable of identifying the differences between the
oncogenic and proto-oncogenic proteins with the possibility of identifying the "cancer-causing"
features within their protein primary structure. In addition, the rational design of bioactive peptide
analogues displaying oncogenic or proto-oncogenic-like activity is presented here.
Background
Bioengineering has emerged as a truly multidisciplinary
field with the aim of improving the quality of human
health through increased biological and medical knowl-
edge facilitating the development of novel devices and
drugs. The ability to predict the functions and three-
dimensional shapes of biological molecules would cer-
tainly be useful in designing such therapeutic drugs. Some
approaches attempt to interrupt the processes occurring in
biochemical pathways in the diseased state by causing a
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key molecule to stop functioning. Drugs may be designed
that bind to the active region and inhibit this key mole-
cule. Most of the drugs that exist today were discovered by
chance, or by trial and error. Unlike this historical method
of drug discovery, by testing of chemical substances on
animals and matching the apparent effects to treatments,
a rational drug design begins with knowledge of specific
chemical responses in the body or target organism, and
tailoring combinations of these to fit a treatment profile.
Though there have been many attempts at such designs in
recent years, they have encountered major hurdles, and it
is only now that the techniques involved seem ready to
produce practical results.
However, such drugs would also have to be designed in
such a way as not to affect other important molecules that
may be similar in appearance to the key molecules.
Sequence homologies are often used to identify such risks.
The structure of the drug molecule that can specifically
interact with the biomolecules can be modeled using
computational tools. These tools can allow a drug mole-
cule to be constructed using knowledge of its structure
and the nature of its active site. However, many of these
approaches are hindered by the practical problems of
chemical synthesis. It has been also suggested to use large
and proteinaceous in nature molecules as drug molecules
instead of small chemical molecules. There have also been
suggestions to make these complex molecules using mes-
senger ribonucleic acid (mRNA) and to employ gene
silencing in therapeutic applications.
Currently, significant scientific effort is being directed to
solve the problem of finding a cure for cancer. New and
advanced drugs and methodologies have been developed
and applied with some degree of success, however, the
battle with cancer still continues. There is an urgent need
for theoretical approaches that are capable of analysing
protein and DNA structure-function relationships leading
to the design of new drugs capable of fighting diseases
such as cancer. The RRM [1,2] represents a non-traditional
computational approach designed for structure-function
analysis of protein and deoxyribonucleic acid (DNA)
sequences and their mutual interactions.
Proteins are polymers built up from amino acids. The
great diversity and versatility of protein sequences are
derived from the properties of the twenty different amino
acid side chains that may exist in a protein molecule and
which are reflected in the wide range of bioactivity of the
formed protein molecules. However, proteins are able to
express their biological functions only by achievement of
a certain active native conformation, the so-called three-
dimensional structure (3-D). Obviously, the particular
function of a given protein and its active 3-D structure are
determined by the sequence of amino acids forming this
particular protein molecule. The protein's biological func-
tion is encrypted within the protein's primary structure,
i.e. the sequence of amino acids. There have been many
attempts to discover the main principles governing the
functional behaviour of proteins. Typical approaches are
either homology characterisation of specific features of
the primary and secondary structure of proteins, or molec-
ular modelling of the protein's 3-D structure. Although
such approaches permit a significant insight into the pro-
tein's structure and active site location, they still do not
provide sufficient knowledge about informational, struc-
tural and physicochemical parameters crucial to the selec-
tivity of protein interactions which can be used for the de
novo design of peptide analogous with desired biological
activity [1,2].
The RRM model [1,2], employed in this study, essentially
belongs to the approaches able to gain the protein's func-
tional and structural information by the analysis of the
amino acid sequences and DNA. The RRM is a physical
and mathematical model that interprets the protein's
sequence linear information using the signal analysis
method of Fourier and Wavelet Transforms. It has been
found through extensive research that proteins with the
same biological function have a common frequency com-
ponent in their numerical spectra. This frequency was
found then to be a characteristic feature for particular pro-
tein biological function or interaction [1,2]. Once this
characteristic frequency is identified, it is possible then to
utilize the RRM to predict the amino acids in the sequence
that predominantly contribute to this frequency and con-
sequently to the observed function. Also it becomes pos-
sible to design peptides having the desired periodicities.
It has been proposed [1,2] that RRM frequency represents
a unique parameter of the interacting sequences and thus,
characterises their mutual interaction. In our previous
work it has been also proposed that this characteristic fre-
quency could represent the oscillations of a physical field,
which are responsible for information transfer between
the interacting bio-molecules [1,2]. Consequently, it is
postulated that the RRM characteristic frequency is a rele-
vant parameter for mutual recognition between bio-mol-
ecules and is significant in describing the interaction
between proteins and their substrates or targets. There-
fore, it can be concluded that the RRM characteristic fre-
quency may dictate the selectivity of protein interactions.
In this paper we discuss in more detail the mathematical
and physical background of the RRM model and its suc-
cessful application to bioactive peptide design and pro-
tein active site predictions. In order to design biologically
active peptides it is of primary importance to determine
which amino acids are responsible for the biological activ-
ity of native proteins. Essentially, systematic mutationNonlinear Biomedical Physics 2007, 1:7 http://www.nonlinearbiomedphys.com/content/1/1/7
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studies would result in the generation of enormous num-
bers of peptides which should be subsequently synthe-
sised and tested to find those peptides that are biologically
active. Here we present the results of our computational
analysis of oncogene and proto-oncogene proteins and
the rational design of bioactive peptide analogues having
the oncogenic or proto-oncogenic-like activity.
Methods
Resonant Recognition Model
Since the binding of therapeutic peptides to appropriate
receptors in the body occurs through intermolecular inter-
actions, the ability to determine which amino acids are
responsible for biological activity is essential. With the
rapid expansion of the protein databases, the identifica-
tion of the biological function of newly sequenced pro-
teins or the determination of their relationships with
defined functional families becomes a real problem.
Therefore, the introduction of additional information
concerning the relationship between amino acids within
the protein sequence would be helpful. The information
encoded in the amino acid sequence ultimately deter-
mines the 3-D structure and biological function of a pro-
tein under physiological conditions. In order to
understand empirical relationships between the amino
acid sequence, structural patterns and functional sites, the
RRM has been invented. The application of the RRM
involves two stages of calculation. The first is the transfor-
mation of the amino acid sequence into a numerical
sequence. Each amino acid is represented by the value of
the Electron-Ion Interaction Potential (EIIP) describing
the average energy states of all valence electrons in a given
amino acid. The EIIP values for each amino acid were cal-
culated using the following general model of pseudo-
potentials [8]:
where q is the change of momentum of the delocalised
electron in the interaction with potential w, while:
where Z is the number of valence electrons of the i-th
component of each amino acid and N is the total number
of atoms in the amino acid. A unique number can thus
represent each amino acid or nucleotide, irrespective of its
position in a sequence. Numerical series obtained in this
way are then analysed by digital signal analysis methods
in order to extract information relevant to the biological
function. As the average distance between amino acid res-
idues in a polypeptide chain is about 3.8 Å, it can be
assumed that the points in the numerical sequence
derived are equidistant. For further numerical analysis the
distance between points in these numerical sequences is
set at an arbitrary value d = 1. Then the maximum fre-
quency in the spectrum is fmax = 1/2d = 0.5. The total
number of points in the sequence influences the resolu-
tion of the spectrum only. Thus, for an N-point sequence
the resolution in the spectrum is equal to 1/N. The n-th
point in the spectral function corresponds to the fre-
quency f = n/N. In order to extract common spectral char-
acteristics of sequences having the same or similar
biological function, the following cross-spectral function
was used:
Sn = XnYn* n = 1,2,..., N/2
where Xn are the Discrete Fourier Transform (DFT) coeffi-
cients of the series x(n) and Yn* are complex conjugate
discrete Fourier transform coefficients of the series y(n).
Peak frequencies in the amplitude cross-spectral function
define common frequency components of the two
sequences analysed. To determine the common frequency
components for a group of protein sequences, the abso-
lute values of multiple cross-spectral function coefficients
M have been calculated as follows:
|Mn| = |X1n|.|X2n|...|XMn| n = 1,2,..., N/2
Peak frequencies in such a multiple cross-spectral func-
tion denote common frequency components for all
sequences analysed. Signal-to-noise ratio (S/N) for each
peak is defined as a measure of similarity between
sequences analysed. S/N is calculated as the ratio between
signal intensity at the particular peak frequency and the
mean value over the whole spectrum. The extensive expe-
rience gained from previous research [1,2,8-10] suggests
that a S/N ratio of at least 20 can be considered as signifi-
cant. The multiple cross-spectral functions for a large
group of sequences with the same biological function
have been named the "consensus spectrum". The presence
of a peak frequency with significant signal-to-noise ratio
in a consensus spectrum implies that all of the analysed
sequences within the group have one frequency compo-
nent in common. This frequency is related to the biologi-
cal function provided the following criteria are met:
￿ Only one peak exists for a group of protein sequences
sharing the same biological function.
￿ No significant peak exists for biologically unrelated pro-
tein sequences.
￿ Peak frequencies are different for different biological
functions.
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In our previous studies, the above criteria have been tested
with over 1000 proteins from 25 functional groups [1,2].
The following fundamental conclusion was drawn from
our studies: one RRM peak frequency characterises one
particular biological function or interaction [1,2]. There-
fore, those peaks are named as the RRM characteristic fre-
quencies. It was shown that proteins and their interacting
targets (receptors, binding proteins, and inhibitors) dis-
play the same characteristic frequency in their interac-
tions. However, it is obvious that one protein can
participate in more than one biological process, i.e.
revealing more than one biological function. Despite pro-
teins and their targets have different biological functions
they can participate in the same biological process. There-
fore, it has been postulated that interacting molecules
"communicate" with each other, i.e. recognise each other
at a distance, on the basis of the same/similar (within the
calculation error) characteristic frequency but opposite
phases at that frequency [2].
However, to appreciate the significance of the RRM char-
acteristic frequency it is important to explore what is
meant by the biological function of proteins. As pointed
out above, each biological process is driven by proteins
that selectively interact with other proteins, DNA regula-
tory segment or small molecules. These interactive proc-
esses involve energy transfer between the interacting
molecules that are highly selective. The question arises
how is this selectivity achieved? In the RRM it is postu-
lated that the selectivity is defined within the amino acid
sequence. It has been shown that proteins and their tar-
gets share the same characteristic frequency but are oppo-
site in phase [1,2] for each pair of interacting
macromolecules. Thus, we conceptualise that RRM char-
acteristic frequencies represent proteins general functions
as well as mutual recognition between a particular protein
and its target (receptor, ligand, etc). As this recognition
arises from the matching of periodicities within the distri-
bution of energies of free electrons along the interacting
proteins, it can be regarded as the resonant recognition.
The RRM model assumes that characteristic frequencies
are responsible for the resonant recognition between mac-
romolecules at a distance. Thus, these frequencies have to
represent oscillations of some physical field which can
propagate through water dipoles. One possibility is that
this field is electromagnetic in nature [1,2].
There is evidence that proteins and DNA have certain con-
ducting properties [12]. If so, then charges would be mov-
ing through the backbone of the macromolecule and
passing through different energy stages caused by the dif-
ferent side groups of various amino acids or nucleotides.
This process provides sufficient conditions for the emis-
sion of electromagnetic waves. Their frequency range
depends on the charge velocity, which in turn depends on
the nature of charge movement (superconductive, con-
ductive, soliton transfer, etc.) and on the energy of the
field that causes charge transfer. The nature of this physi-
cal process is still unknown; however, some models of
charge transfer through the backbone of macromolecules
have been accepted [13-15]. To simplify the calculations,
we assumed the electron transfer is attributed to the differ-
ence of the free EIIP at the amino group (NH2) and car-
boxyl (COOH) group of the protein molecule. According
to the theory of pseudo-potentials [16], this potential
energy difference is:
W = W(COON) - W(NH2) = 0.13 Ry
This energy difference allows for a maximum velocity of
the electrons of:
where e is the electron charge, and m is electron mass.
Therefore
V < 7.87·105 m/sec
As an inherent assumption is the amino acids in the pro-
tein sequence are equidistant at:
d = 3.8 Å
Then, the maximum frequency that could be emitted dur-
ing the electron transfer is
Fmax <V/2d
or
Fmax < 1015 Hz
while the corresponding wavelength is
Lmin > 330 nm
The minimum frequency that could be emitted depends
on the total length of the protein
Fmin = 2 Fmax/N
where N is the total number of amino acids in the protein.
For example with proteins of 200 amino acids in length,
the minimum frequency is
Fmin < 1013 Hz
and the corresponding wavelength is
Ve W m max = 2Nonlinear Biomedical Physics 2007, 1:7 http://www.nonlinearbiomedphys.com/content/1/1/7
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Lmax < 30 000 nm
This range from 30000 nm to 300 nm is very wide, start-
ing from the very low infrared through the visible to the
ultraviolet regions [1,2].
To establish the possibility that macromolecular interac-
tions are based on the resonant energy transfer between
interacting molecules, we compared our computational
predictions with a number of published experimental
results (Table 1). This assumption has been studied for a
number of examples that include:
￿ Laser light growth promotion of cells using the particu-
lar frequencies of light producing a similar effect to that
due to the presence of growth factor proteins [17],
￿ Chymotrypsin activation (increase of enzyme activity)
achieved by laser light radiation in the range 850–860 nm
[18],
￿ Activation of highly homologous plant photoreceptors
which, although being very homologous, absorb different
wavelengths of light [19],
￿ Photo-activated proteins (e.g. rhodopsins, flavodoxins
etc.), that absorb light through the prosthetic group but
where frequency selectivity of this absorption and conse-
quent activation is defined by the protein sequence
[20,21].
All these results imply that specificity of protein interac-
tions is based on the resonant electromagnetic energy
transfer at the specific frequency, observed for each inter-
action. The numerical frequencies that have been
obtained similarly by the RRM for various other groups of
visible light-absorbing proteins are compared with their
corresponding characteristic absorption frequencies in
Table 1 and this linear correlation is shown in Figure
1[1,2]. A result of considerable significance is that the scal-
ing factor between these two sets of data is almost con-
stant about the value of K = 200 [1,2]. Thus, a strong linear
correlation appears to exist between the numerical charac-
teristic frequencies defined by the RRM and the experi-
mentally determined frequencies corresponding to the
electromagnetic radiation absorption of such proteins.
From this correlation it can be observed that the full range
of wavelengths, which can be related to RRM characteristic
frequencies, is over 400 nm. This finding is in complete
accord with the frequency range previously associated to
the RRM spectra and calculated from the charge velocities
through the protein backbone. It can be now inferred
from both correlations that approximate wavelengths in
real frequency space can be calculated from the RRM char-
acteristic frequencies for each biologically related group of
sequences. Furthermore, these calculations can be used to
predict the wavelength of visible and near-infrared irradi-
ation which may produce a biological effect [14,15].
Once the characteristic frequency for the particular biolog-
ical function or interaction is determined, it becomes pos-
sible to identify the individual "hot spot" amino acids that
contributed most to this specific characteristic frequency
and thus, possibly to the observed biological behaviour of
the protein.
"Hot spots" in terms of the RRM and 3-D protein 
structures
It is known that proteins cannot express their biological
function until they achieve a certain active 3-D conforma-
tion. By identifying the characteristic frequency of a partic-
ular protein, it is possible to predict then which amino
acids in the sequence predominantly contribute to the fre-
quency and consequently to the observed function
[1,2,8,9]. Since the characteristic frequency correlates with
the biological function, the positions of the amino acids
that are most affected by the change of amplitude at the
particular frequency can be defined as "hot spots" for the
corresponding biological function. The strategy for this
prediction includes the following steps:
￿ To determine the unique characteristic frequency for the
specific biological function by multiple cross-spectral
analysis for the group of sequences with the correspond-
ing biological function.
￿ To alter the amplitude at this characteristic frequency in
the particular numerical spectrum. The criterion used for
identifying the critical characteristic frequency change is
the minimum number of "hot spot" amino acids that are
least sensitive to further changes in the amplitude of the
characteristic frequency.
￿ To derive a numerical sequence from the modified spec-
trum using DFT.
It is known that a change in amplitude at one frequency
in the spectrum causes changes at each point in the
numerical sequence. Thus a new numerical series is
obtained where each point is different from those in the
original series. Detecting the amino acids corresponding
to each element of this new numerical sequence can then
be achieved using tabulated values of the EIIP or other
appropriate amino acid parameters. The amino acids in
the new sequence that differs from the original ones reside
at the points mostly contributing to the frequency. These
hot spots are related to this frequency and to the corre-
sponding biological function. The procedure described
was used in a number of examples: IL-2 [9], hemoglobins,
myoglobins and lysozymes [8], chymotrypsins [12], glu-Nonlinear Biomedical Physics 2007, 1:7 http://www.nonlinearbiomedphys.com/content/1/1/7
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cagons, TNFs [10], EGFs, FGFs [2]. These examples have
shown that such predicted amino acids denote residues
crucial for protein functions. Consequently, these "hot
spot" amino acids are found spatially clustered in the pro-
tein's 3-D structure in and around the protein active site.
As these specific amino acids most strongly influence the
characteristic frequency, their cluster does represent a site
in the protein where the signal of the characteristic fre-
quency for the specific protein property is dominant. As
this cluster of amino acids has been found positioned in
and around the active site (Fig. 2), it is proposed that these
specific amino acids play a crucial role in determining the
structure of the active site and possibly, the active struc-
ture of the whole molecule [8,11].
Bioactive Peptide Design
Following the determination of the RRM characteristic fre-
quencies and corresponding phases for particular biolog-
ical functions, it is possible to design amino acid
sequences having those spectral characteristics only. It is
expected that the designed peptide will exhibit the desired
biological activity. The strategy for the design of such
defined peptides is as follows:
1) In the multiple cross-spectral function of the group of
protein sequences sharing the corresponding biological
function to determine the unique RRM frequency that
characterises this specific biological function/interaction.
2) To define the characteristic phases at the characteristic
frequencies for the particular protein that is chosen as the
parent for agonist/antagonist peptide design.
3) To derive a numerical sequence from the known char-
acteristic frequencies and phases. This can be done by
summing sinusoids of the particular frequencies, ampli-
tudes and phases. The length of the numerical sequence is
defined by the appropriate frequency resolution, and the
required peptide's length.
4) To determine the amino acids that corresponds to each
element of the new numerical sequence. It can be
achieved by the tabulated EIIP or other appropriate amino
acid parameters [1,2,10].
In our previous research these procedures have been
applied to different examples of proteins [3,4,7], aiming
at the design of peptide analogous having the same func-
tional activity as their parent proteins:
Table 1: The RRM frequencies and characteristic absorption frequencies of different visible light-absorbing protein groups and their 
scaling factor, K [2]
protein nm rrm cm-1 K
cyt c 415 0.473 24096.3855 196
blue 430 0.475 23255.814 204
green 540 0.355 18518.5185 191
red 570 0.346 17543.8596 197
hem. 14770 0.02 677.04807 295
purple 860 0.281 11627.907 241
flavodoxin 470 0.379 21276.5957 178
igf 400 0.492 25000 196
fgf 441.6 0.453 22644.9275 200
insulin 552 0.344 18115.942 189
growth f. 633 0.293 15797.7883 185
650 0.293 15384.6154 190
pdgf 830 0.242 12048.1928 200
chymotr. 851 0.236 11750.8813 200
calculative 400 0.5 25000 200
Linear correlation between RRM frequencies and corre- sponding absorption frequencies of different visible light- absorbing protein groups Figure 1
Linear correlation between RRM frequencies and corre-
sponding absorption frequencies of different visible light-
absorbing protein groups.
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Multiple cross-spectral function of: a) oncogene and b) proto-oncogene proteins Figure 2
Multiple cross-spectral function of: a) oncogene and b) proto-oncogene proteins. The prominent peak(s) denote common fre-
quency components. The abscissa represents RRM frequencies, and the ordinate is the normalized intensity.
(a) 
(b) Nonlinear Biomedical Physics 2007, 1:7 http://www.nonlinearbiomedphys.com/content/1/1/7
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￿ The RRM has been applied to structure-function studies
with basic fibroblast growth factor (bFGF) [3]. Property-
pattern characteristics for biological activity and receptor
recognition for a group of FGF-related proteins were
defined and then used to aid the design of a set of peptides
which can act as bFGF antagonists. Molecular modelling
techniques were then employed to identify the peptide
within this set with the greatest conformational similarity
to the putative receptor domain of bFGF. The 16 mer pep-
tide, which exhibits no sequence homology to bFGF,
antagonised the stimulatory effect of bFGF on fibroblast
[3H]thymidine incorporation and cell proliferation, but
exerted no effect itself in these in vitro bioassays [3].
￿ The interaction between HIV virus envelope proteins
and CD4 cell surface antigen has a central role in the proc-
ess of virus entry into the host cell. Thus, blocking the
interaction between the envelope glycoproteins and CD4
surface antigen, known to be the HIV receptor, should
inhibit infection [4]. For this purpose, six peptides, each
20 amino acids in length, were designed using the RRM
procedure. To validate the RRM predictions, the peptides
designed were evaluated experimentally [4]. These inves-
tigations were performed initially by evaluating the reac-
tivity and cross-reactivity of all such designed peptides
with the corresponding antibodies [4]. The results
obtained have shown significant cross-reactivity to the
polyclonal antibodies raised against peptides that share at
least one characteristic frequency and phase at this fre-
quency. The results provide experimental confirmation of
the concept that RRM frequency characteristics reflect
important parameters associated with bio-molecular rec-
ognition and in particular antibody-antigen recognition.
In our previous study [7] the RRM was employed for the
analysis of forty six oncogene and fifteen proto-oncogene
proteins in determining the structure-function relation-
ship among these sequences. The common frequencies
have been determined computationally that represent the
characteristic features of their common biological activity,
i.e. the ability to promoter uncontrolled cell proliferation,
in case of the oncogene proteins, and normal cell growth
for proto-oncogenes. This study emphasises the de novo
design of peptide analogues only on the basis of the fre-
quencies and phases predicted computationally. Ulti-
mately, these designed peptides would exhibit the desired
oncogene or proto-oncogenic-like activity as their paren-
tal protein.
Results and discussion
Cancer cells development is attributed to different muta-
tions and alterations in DNA. DNA controls all cell bio-
logical activities. Each gene serves as a recipe on how to
build a protein molecule. Proteins perform important
tasks for the cell functions or serve as building blocks. The
flow of information from the genes determines the pro-
tein composition and thereby the functions of the cell.
Investigations of cellular and molecular mechanisms of
uncontrolled cell proliferation associated with their trans-
formation have resulted in the identification of a large
number of genes (oncogenes), the products of which are
involved in cell neoplasia.
The oncogenic family of proteins is generally involved in
regulation of cell proliferation through regulation of DNA
transcription. This regulation can be achieved indirectly
via different signal pathways as it is in the case of tyrosine
kinase oncogene products eg. src, ros, fps, fes and yes or
directly by protein-DNA binding, as it is the case of
nuclear proteins like myc, fos and myb. There is also a
group of oncogene products including ets-, sfi- and ras –
related proteins, for which in vivo biological functions and
pathways of action have still to be fully defined
[2,7,22,23]. The Ha-ras oncogene family (p21 proteins)
are known to function in vitro as GTP binding proteins
involved in signal transduction pathways, as well as in
control of DNA synthesis, cell transformation, prolifera-
tion and differentiation [2,7,22,23]. Although it is known
that the cellular, proto-oncogenic form of p21 is involved
in control of cell proliferation, while the oncogenic form
is additionally involved in cell transformation and differ-
entiation, the exact mode of action and signal pathways of
the Ha-ras p21 proteins (cellular, proto-oncogenic and
oncogenic) still remain unknown [22,23].
The RRM approach has been applied here to a group of
forty six oncogene proteins, with the aim of ascertaining
their RRM frequency characteristics. The obtained RRM
characteristic frequencies are as follows: f1 = 0.0322 ±
0.004, S/N = 297.29 and f2 = 0.0537 ± 0.004, S/N = 77.25.
As is evident from Figure 2, both identified frequencies
with significantly different amplitude ratios are observed
in the cross-spectral function of all oncogene proteins.
The prominent frequency component at f1 = 0.0322 ±
0.004, S/N = 297.29, common to the analysed sequences,
characterises a common biological behaviour of this
group of oncogene products, i.e. the ability to promote an
uncontrolled cell growth and proliferation. The same
RRM procedures have been applied for analysis of fifteen
proto-oncogene sequences (Fig. 2). As can be observed
from Figure 2 there is a prominent peak identified at f2 =
0.0537 ± 0.004, S/N = 199.74. This characteristic fre-
quency determined represents a characteristic feature of
all proto-oncogene sequences analysed and corresponds
to their common biological behaviour, i.e. normal cell
growth. It is noteworthy that the same frequency f2 =
0.0537 ± 0.004, S/N = 77.25 was identified as the less sig-
nificant peak existing in multiple cross-spectral function
of oncogene proteins. According to the RRM each specific
biological function of the protein is characterised by a sin-Nonlinear Biomedical Physics 2007, 1:7 http://www.nonlinearbiomedphys.com/content/1/1/7
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gle frequency [7]. Thus, two peak frequencies identified
within the RRM for forty six oncogene proteins f1 = 0.0322
± 0.004, S/N = 297.29 and f2 = 0.0537 ± 0.004, S/N =
77.25, correspond to two different protein functions of
these protein sequences.
In this study Ha-ras p21 sequence (Harvey Murine sar-
coma virus) was used as a protein model for the peptide
design. The RRM procedures have been applied to Ha-ras
p21 protein to design the peptide that exhibits ras-like
activity, i.e. ability to transform cells. The design of six de
novo peptides A-F was based on two characteristic frequen-
cies and phases determined for the entire functional
group of oncogene proteins f1 = 0.0322, φ1 = 1.641 and f2
= 0.0537, φ2 = 2.460
Each peptide has either one or both frequencies with the
same or opposite phases at these frequencies as presented
in the Fig 3.
Here the RRM has been applied to Ha-ras p21 protein
sequence to design the peptide that will exhibit ras-like
activity, i.e. ability to transform cells.
The original protein is presented below:
Transforming protein (H-ras) – Harvey murine sarcoma
virus, 241 amino acids sequence
MPAARAAPAADEPMRDPVAPVRAPALPRPAPGAVAPAS-
GGARAPGL
AAPVEAMTEYKLVVVGARGVGKSALTIQLIQNHFVDEY-
DPTIEDSYR
KQVVIDGETCLLDILDTTGQEEYSAMRDQYMRTGEG-
FLCVFAINNTK
SFEDIHQYREQIKRVKDSDDVPMVLVGNKCDLA-
GRTVESRQAQDLAR
SYGIPYIETSAKTRQGVEDAFYTLVREIRQHKLRKLNPP-
DESGPGCMSC
KCVLS
The peptide analogous has been designed on the basis of
defined frequencies and phases:
f1 = 0.0322 φ1 = 1.641 (characteristic frequency of onco-
gene proteins)
f2 = 0.0537 φ2 = 2.460 (characteristic frequency of proto-
oncogene proteins)
The designed peptides (18 amino acids sequence):
1) f1 = 0.0322, φ1 = -1.641, f2 = 0.0537, φ2 = -2.460
A: NLNEPAWQTRDDDDDRFM
2) f1 = 0.0322, φ1 = -1.641
B: LNEPHAYWQCRRDDDDDD
3) f2 = 0.0537, φ2 = -2.460
C: EILEPAWQRDDDDDRQWK
4) f1 = 0.0322, φ1 = 1.641, f2 = 0.0537, φ2 = 2.460
D: DRMWKPEILGPHKYYWWY
5) f1 = 0.0322, φ1 = 1.641
E: DDDRFMQWAAPPEILINV
6) f2 = 0.0537, φ2 = 2.460
F: CWAHEILEPAWQRDDDDD
It is known that proto-oncogene proteins are the products
of proto-oncogenes. Generally, they do not have onco-
genic or transforming properties but are involved in the
normal regulation or differentiation of cell growth. How-
ever, proto-oncogenes can promote cancer development
only if they acquire new properties as a result of mutations
at which point they are known as oncogenes. Most com-
mon cancers involve modification of certain proto-onco-
genes. Determination of two distinct characteristic
frequencies, which correspond to two different functions,
i.e. normal cell growth (proto-oncogenes) and uncon-
trolled cell transformation (oncogenes), reveal that the
Schematic presentations of the designed peptides [4] Figure 3
Schematic presentations of the designed peptides [4].
Peptide/frequency f1 f2 M1 M2
________________________________________
A* * - -
B* -
C* -
D* * + +
E* +
F* +
_______________________________________Nonlinear Biomedical Physics 2007, 1:7 http://www.nonlinearbiomedphys.com/content/1/1/7
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RRM approach can assist in distinguishing between the
oncogene and proto-oncogene activity of oncogene pro-
teins. Thus, these results can lead to the conclusion that
the RRM approach is capable of identifying "cancerous"
features (frequencies) within the protein primary struc-
tures of the studied proteins. The RRM presents a rational
approach in generating phenotypic diversity in proteins
that will complement the existing, more random muta-
genic approaches currently used in directed evolution, or
the more time consuming approach based on the prior
knowledge of a 3-D structure. The possibility to computa-
tionally calculate the frequencies and phases with the fol-
lowing possibility to produce the desired biological
mutations and alterations in proteins would benefit the
development of new non-invasive treatments and tech-
nologies. In addition, the de novo peptides designed on the
basis of the oncogenic (cancerous) and proto-oncogenic
(normal) frequencies determined within the RRM might
be used in the development of new testing and treatment
procedures for cancer. It is particularly important to note
that the RRM approach is capable of identifying the com-
mon (general) cancerous characteristic and thus it may
lead to the development of a vaccine for the treatment of
a wider range of cancers.
Conclusion
We have shown previously using the RRM concepts that
digital signal processing methods can be used to analyse
linear sequences of amino acids to reveal the informa-
tional content of proteins and determine functionally sig-
nificant amino acids of the analysed proteins. This study
extends the utility of the RRM procedures to oncogene
and proto-oncogene proteins. It has been also shown that
the RRM is capable of identifying the difference between
oncogenes and proto-oncogenes and thus, identifying
general "cancerous" features within oncogene protein pri-
mary structures. If such feature can be identified then it
would be possible to validate unknown or modified pro-
teins as well as relevant DNA sequences for their possible
cancerous activity. In addition, as shown here, it is possi-
ble to design peptides which would have only this "can-
cerous" characteristic. Such peptides are predicted to carry
the common characteristic of all oncogenes and thus, they
can be used for the development of a vaccine, which could
be then preventive for most kind of cancers.
Hence, once again, it has been shown that the RRM pro-
vides a new strategy to characterise and interpret the infor-
mational content of proteins, particularly oncogene
proteins relevant to cellular transformation. It also pro-
vides the guidelines for a wide variety of protein and pep-
tide structural manipulations, e.g., protein engineering by
recombinant techniques could be undertaken based on
the RRM predictions for the redesign of specific protein or
peptide variants with modified biological properties. This
novel prediction scheme can be used to facilitate the struc-
ture-function studies of different proteins and thus, could
result in significant cost saving and improvement in cur-
rent biotechnology and quality of new biomaterials.
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